Millennium Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.68M Buy
120,900
+17,700
+17% +$1.46M ﹤0.01% 2202
2025
Q4
$8.8M Sell
103,200
-59,000
-36% -$4.84M ﹤0.01% 2394
2025
Q3
$12.6M Sell
162,200
-409,300
-72% -$32M 0.01% 2138
2025
Q2
$44.7M Buy
571,500
+15,600
+3% +$1.16M 0.02% 892
2025
Q1
$40.3M Sell
555,900
-680,800
-55% -$48.7M 0.02% 920
2024
Q4
$91.6M Buy
1,236,700
+156,500
+14% +$11M 0.04% 434
2024
Q3
$71.3M Buy
1,080,200
+588,900
+120% +$42.8M 0.03% 608
2024
Q2
$45.4M Buy
491,300
+93,700
+24% +$8.3M 0.02% 868
2024
Q1
$38M Sell
397,600
-250,100
-39% -$21M 0.02% 1021
2023
Q4
$49.4M Sell
647,700
-465,500
-42% -$32.4M 0.02% 804
2023
Q3
$77.1M Buy
1,113,200
+365,600
+49% +$29.4M 0.04% 486
2023
Q2
$70.5M Buy
747,600
+695,000
+1,321% +$60.4M 0.03% 520
2023
Q1
$4.35M Buy
52,600
+17,900
+52% +$1.41M ﹤0.01% 2729
2022
Q4
$2.59M Sell
34,700
-188,100
-84% -$14.5M ﹤0.01% 3350
2022
Q3
$18.4M Buy
222,800
+207,300
+1,337% +$19.9M 0.01% 1432
2022
Q2
$1.47M Sell
15,500
-4,500
-23% -$466K ﹤0.01% 4006
2022
Q1
$2.35M Sell
20,000
-29,500
-60% -$3.31M ﹤0.01% 3719
2021
Q4
$6.41M Sell
49,500
-152,500
-75% -$17.8M ﹤0.01% 2644
2021
Q3
$22.9M Sell
202,000
-19,500
-9% -$2.23M 0.01% 1205
2021
Q2
$22.9M Buy
221,500
+170,000
+330% +$16M 0.01% 1088
2021
Q1
$4.31M Sell
51,500
-478,500
-90% -$40.5M ﹤0.01% 2744
2020
Q4
$48.4M Buy
530,000
+509,600
+2,498% +$42.3M 0.03% 474
2020
Q3
$1.63K Sell
20,400
-109,600
-84% -$8.55M ﹤0.01% 2756
2020
Q2
$8.98M Sell
130,000
-80,000
-38% -$5.69M 0.01% 1294
2020
Q1
$13.2M Buy
210,000
+179,100
+580% +$12.9M 0.03% 672
2019
Q4
$2.4M Sell
30,900
-1,265,100
-98% -$98.8M ﹤0.01% 2487
2019
Q3
$95M Buy
1,296,000
+1,226,700
+1,770% +$86.2M 0.15% 123
2019
Q2
$4.27M Buy
69,300
+46,800
+208% +$2.83M 0.01% 1903
2019
Q1
$1.44M Sell
22,500
-36,000
-62% -$2.05M ﹤0.01% 2636
2018
Q4
$2.99M Sell
58,500
-2,381,700
-98% -$121M ﹤0.01% 1954
2018
Q3
$142M Buy
2,440,200
+1,720,200
+239% +$84.1M 0.17% 108
2018
Q2
$34.9M Buy
720,000
+377,700
+110% +$17.6M 0.05% 581
2018
Q1
$15.9M Buy
342,300
+312,300
+1,041% +$13.6M 0.02% 1015
2017
Q4
$1.13M Sell
30,000
-120,000
-80% -$4.4M ﹤0.01% 2630
2017
Q3
$5.47M Buy
+150,000
New +$5.72M 0.01% 1620
2017
Q1
Sell
-300,000
Closed -$9.37M 3576
2016
Q4
$9.37M Buy
300,000
+90,000
+43% +$2.92M 0.02% 961
2016
Q3
$8.44M Sell
210,000
-300,000
-59% -$11.3M 0.01% 1027
2016
Q2
$17M Buy
510,000
+285,000
+127% +$9.75M 0.04% 604
2016
Q1
$6.62M Buy
+225,000
New +$6.21M 0.02% 1082
2015
Q4
Sell
-150,000
Closed -$3.55M 3506
2015
Q3
$3.55M Buy
+150,000
New +$3.62M 0.01% 1533
2015
Q1
Sell
-118,200
Closed -$2.51M 3723
2014
Q4
$2.51M Sell
118,200
-18,000
-13% -$362K 0.01% 1834
2014
Q3
$2.32M Buy
136,200
+6,000
+5% +$94.7K 0.01% 1775
2014
Q2
$1.86M Sell
130,200
-1,194,600
-90% -$16.2M 0.01% 1828
2014
Q1
$16.4M Buy
1,324,800
+706,800
+114% +$8.16M 0.05% 545
2013
Q4
$6.77M Sell
618,000
-517,200
-46% -$5.83M 0.02% 956
2013
Q3
$13.2M Buy
1,135,200
+894,600
+372% +$10.5M 0.04% 555
2013
Q2
$2.69M Buy
+240,600
New +$2.85M 0.01% 1404

Other funds holding EW

Millennium Management's EW Position: Q1 2026 in Review

Millennium Management reduced its Edwards Lifesciences (EW) stake by 70% in Q1 2026, selling an estimated $353M and leaving 1,796,821 shares worth $144M. The position accounts for 0.06% of the portfolio, ranked #308.

Millennium Management first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $523M in Q2 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Millennium Management held 1,796,821 shares of Edwards Lifesciences worth $144M as of Q1 2026.
  • Millennium Management sold 4,284,117 Edwards Lifesciences shares in Q1 2026, an estimated $353M.
  • Edwards Lifesciences made up 0.06% of Millennium Management's portfolio in Q1 2026, its #308 holding.
  • Millennium Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Millennium Management's Edwards Lifesciences position peaked at $523M in Q2 2025.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.